Would Syntra5 be superior to Liponine for improving fasting glucose levels, insulin resistance and metabolic syndrome common to Type II diabetes?

We see each product having advantages, and this will be user-specific. So either one is a good starting point and deserving of a trial. In the absence of a benefit after at least a month of use, switching to the other product would still be worth doing because there are some mechanistic differences in the makeup of the constituents, and the other issue is how the user's system handles the formulation. So tissue levels and the overall bioavailability can differ, but both are very worthwhile adjuncts that will be superior to what can be done with existing pharmaceuticals for helping people with type II diabetes.